Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab, Valproate, and Radiosurgery in Recurrent Glioblastoma
NCT02648633Phase 1Terminated
- Sponsor
- University of Virginia
- Start
- May 2016
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in glioblastoma (GBM), sponsored by University of Virginia. Primary endpoints: Feasibility based on number of subjects who complete 4 doses of nivolumab at 3 months and Incidence of adverse events. Started May 2016; status: terminated.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02648633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02648633.